1.3 Parallel session: Maternal and child health

Session detail

OA-260 - Neuropsychiatric adverse effects of dolutegravir versus efavirenz 400mg based first line antiretroviral therapy in HIV infected pregnant women in Uganda: a randomised clinical trial

Speakers:
  • Hadijja Namwase, Karolinska Institutet, Uganda

OA-684 - Prevalence of eligible pregnant women with hepatitis B for antiviral treatment, mother-to-child transmission of HBV infection and birth dose vaccination in Ethiopia: prospective follow-up study

Speakers:
  • Senait Tadesse, Bahir Dar University, Ethiopia

OA-371 - Circulating anodic antigen (CAA) as a diagnostic marker for Schistosoma haematobium in pregnant women co-infected with Plasmodium falciparum in Lambaréné, Gabon: implications for neonatal outcomes

Speakers:
  • Yabo Honkpehedji, Centre de Recherches Médicales de Lambaréné (CERMEL), Gabon

OA-506 - Adverse events after measles and Bacillus Calmette-Guérin (BCG) vaccinations of women of fertile age in Guinea-Bissau: a nested study within an open-label placebo-controlled randomised trial

Speakers:
  • Isaquel Silva, Bandim Health Project, Guinea-Bissau

OA-190 - Association between Epstein-Barr virus reactivation and severe malaria in pregnant women in a malaria-endemic region of Cameroon

Speakers:
  • Ide Armelle Djuidje Chatue, University of Yaounde I, Cameroon

OA-637 - Neurocognitive function among infants living with HIV with and without severe pneumonia in Uganda

Speakers:
  • Damalie Nalwanga, Makerere University, Uganda